Regeneron Pharmaceuticals (NASDAQ:REGN) reported earnings of $5.23 per share beating Walls Streets expectations.

ME Staff
-
0

Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q4 2017 earnings this Morning, coming in at $5.23 per share, beating Wall Street’s estimates of $4.52 per Share. Revenue for the quarter came in at $1.58 billion beating analyst estimates of $1.50 billion

Recent Insider Trading for Regeneron Pharmaceuticals (NASDAQ:REGN)

  • On 10/5/2017 Michael S Brown, Director, sold 1,500 with an average share price of $475.00 per share and the total transaction amounting to $712,500.00.
  • On 9/29/2017 Charles A Baker, Director, sold 2,000 with an average share price of $450.00 per share and the total transaction amounting to $900,000.00.
  • On 9/6/2017 Robert E Landry, SVP, sold 663 with an average share price of $498.60 per share and the total transaction amounting to $330,571.80.
  • On 9/5/2017 Robert E Landry, CFO, sold 189 with an average share price of $501.06 per share and the total transaction amounting to $94,700.34.
  • On 8/31/2017 Robert E Landry, SVP, sold 427 with an average share price of $493.43 per share and the total transaction amounting to $210,694.61.
  • On 8/25/2017 Sanofi, Major Shareholder, bought 72,378 with an average share price of $481.36 per share and the total transaction amounting to $34,839,874.08.



    Recent Trading for Regeneron Pharmaceuticals (NASDAQ:REGN)
    Shares of Regeneron Pharmaceuticals closed the previous trading session at 346.48 up +11.87 3.55% with 342.0299987792969 shares trading hands.